Company IN VITRO DIAGNOSTIC MARKET € 33 BLN Profile In vitro diagnostics consist in detecting the presence of some molecules (that are indicative of a particular disease) in patient’s
biological fluids, such as blood, urine, cerebrospinal fluid. To that end,
Diasorin is an Italian company listed on the stock market in the FTSE MIB Index. It is a global leader in the field of biotechnologies: for over 40 years the company has been developing, producing and commercializing reagent kits for the in vitro diagnostics worldwide, in particular in the immunodiagnostics and molecular diagnostics segments. To run reagents, Diasorin provides specific instruments to clients for both immunodiagnostics and molecular diagnostics
patient’s biological fluids are put in a test tube (hence the term in vitro) with some chemical substances to create a reaction. The chemical
23.0%
21.0%
IMMUNODIAGNOSTIC
CLINICAL CHEMISTRY
reaction shows the presence of a particular molecule in the patient’s body, indicating a specific disease. The Diasorin Group is active in the area of in vitro diagnostics, especially
8.5%
in the fields of immunodiagnostics and molecular diagnostics. These
MOLECULAR DIAGNOSTIC
21.0%
SELF-MONITORING BLOOD GLUCOSE
two diagnostic techniques use different reagents to detect specific molecules of great diagnostic importance, in patients’ biological fluids. Immunodiagnostic tests use antibodies as key reagents, while molecular diagnostic tests use nucleic acids.
8.5% 6.0% 6.0%
OTHER
MICROBIOLOGY POINT OF CARE
6.0%
HEMATOLOGY
IMMUNODIAGNOSTICS € 7 BLN 9.3%
BONE & MINERAL
12.1% INFECTIOUS DISEASES
12.9% Cardiac markers
6.4% AUTOIMMUNITY 5.7% ALLERGY 3.6%
Immunodiagnostics is the technology used for the
detection and, in some
cases, quantification of particular molecules in patients’ biological fluids (blood,
DRUG MONITORING & OTHERS
4.3%
GI STOOL TESTING
for example) by the use of antibodies. The antibody is a protein molecule that nowadays can be generated in laboratories. This molecule has the property of specifically recognizing (that is to physically bind to) a target molecule (known as antigen) whose presence means that a particular disease is present.
25.7% ONCOLOGY & ENDOCRINOLOGY
20.0%
hepatitis & RETROVIRUS
MOLECULAR DIAGNOSTICS € 3 BLN While immunodiagnostic tests can detect small molecules (for example sex hormones, such as estradiol, progesterone, testosterone) or protein molecules (such as antigens made by infectious agents) in patients’ biological fluids, molecular diagnostic tests can detect nucleic acids (DNA and RNA) that are specific to certain diseases, through the analysis of patients’ biological fluids.